Rheumatoid Arthritis and Omega-3 Fatty Acids (EPA/DHA)

Deep Dive

From a western perspective, omega‑3 fatty acids intersect RA biology at multiple control points of inflammation. EPA and DHA are incorporated in... From a western perspective, omega‑3 fatty acids intersect RA biology at multiple control points of inflammation. EPA and DHA are incorporated into phospholipid membranes of leukocytes and synovial cells, displacing arachidonic acid and shifting the substrate pool for cyclooxygenase and lipoxygenase enzymes. This biochemical change yields fewer pro‑inflammatory eicosanoids (e.g., PGE2, LTB4) that otherwise amplify synovial hyperplasia and neutrophil chemotaxis. Concomitantly, marine omega‑3s serve as precursors to specialized pro‑resolving mediators—resolvins, protectins, and maresins—that actively promote resolution, limit neutrophil infiltration, and enhance efferocytosis. In vitro and ex vivo work demonstrates dampened NF‑κB signaling and modest reductions in TNF‑α, IL‑1β, and IL‑6, aligning with mechanisms targeted by biologics. Clinical trials have translated these mechanistic insights into modest adjunctive benefits. Randomized controlled trials and meta‑analyses report small but meaningful improvements in pain, morning stiffness, and tender joint counts, with a particularly consistent decrease in NSAID consumption. Effects on composite disease activity (e.g., DAS28) are present but generally modest. The time course—8 to 12 weeks—matches the kinetics of membrane remodeling, suggesting adherence and duration matter. A modern trial in early RA hinted that fish oil added to DMARDs may support remission and reduce treatment escalation, though contemporary, adequately powered studies alongside current treat‑to‑target regimens are still needed. In practice, omega‑3s are viewed as adjuncts rather than substitutes for DMARDs or biologics. Diet quality also matters: regular fatty fish intake appears beneficial and aligns with cardiometabolic risk reduction, an important consideration in RA. Safety is favorable overall; gastrointestinal upset and fishy aftertaste are the most common issues. While large analyses suggest minimal bleeding risk at commonly studied intakes, clinicians typically monitor patients on anticoagulants or antiplatelets and consider perioperative plans. No major pharmacokinetic interactions with DMARDs are established, but careful coordination with the care team supports safe integration.